WEB-2086
PAF receptor antagonist / Potent and selective antagonist of the platelet activating factor (PAF) receptor (Ki = 16.3 nM)1. Displays an activity profile which includes antiinflamatory, antiangiogenesis and anticancer activity2. Along with leukotriene antagonists, cooperatively provides a robust anti-inflammatory effect regulating PMNL migration and edema formation3. Displays analgesic effects in animal models of neuropathic pain4. Active in vivo.
Biochemicals & reagents
105219-56-5
Apafant
1) Dent et al. (1989), Characterization of PAF receptors on human neutrophils using the specific antagonist WEB 2086. Correlation between receptor binding and function; FEBS Lett., 244 365 2) Cellai et al. (2006), Growth inhibition and differentiation of human breast cancer cells by PAFR antagonist WEB-2086; Br. J. Cancer, 94 1637 3) Bitencourt et al. (2013), Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury; J. Cell. Mol. Med., 17 1554 4) Motoyama et al. (2013), Pain-releasing action of platelet-activating factor (PAF) antagonists in neuropathic pain animal models and the mechanisms of action; Eur. J. Pain, 17 1156
-20°C
TARGET: PAF (Platelet-activating factor) receptor -- PATHWAY: Coagulation; Cell migration -- RESEARCH AREA: Angiogenesis; Neuroscience -- DISEASE AREA: Inflammation; CancerPain